Specifically, CYThigh cancer patients exhibited significantly higher levels ofPD-L1 and CTLA-4, among other immune checkpoints, and responded better to ICI therapies [25,26,27,52,81,108,109,111,112]. Here, CTLA4 is linked to cancer.